Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on August 6, 2025
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering
GlobeNewswire
·
August 6, 2025
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), …
Profusa, Inc. Provides Strategy Overview and Business Update for Investors
GlobeNewswire
·
August 6, 2025
BERKELEY, Calif, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an …
Lung Health Foundation Encouraged by Ontario’s $1.8 Billion Primary Care Investment and Hopes Vital Respiratory Services Will Be Included
GlobeNewswire
·
August 6, 2025
TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As Ontario commits $1.8 billion to expand access to team-based primary care, the Lung Health Foundation (LHF) is calling on the government to take a vital next step: ensure that Respiratory Therapists and …
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
GlobeNewswire
·
August 6, 2025
VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMS Amifampridine may be considered as a supportive care treatment Guideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader VGCC diagnostic …
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
GlobeNewswire
·
August 6, 2025
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, …
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
GlobeNewswire
·
August 6, 2025
REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results …
Bionano to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 6, 2025
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, …
NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit
GlobeNewswire
·
August 6, 2025
SANTA ANA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer …
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire
·
August 6, 2025
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today …
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 6, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …
NEXGEL to Report Second Quarter 2025 Financial Results on August 12th
GlobeNewswire
·
August 6, 2025
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for …
Sofwave to Participate in 10th Annual Needham Virtual MedTech & Diagnostics Conference
GlobeNewswire
·
August 6, 2025
SAN CLEMENTE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief …
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
GlobeNewswire
·
August 6, 2025
Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the …
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
PRINCETON, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Cardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD-750, a Novel PDE9 inhibitor, in Heart Failure
GlobeNewswire
·
August 6, 2025
CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ejection fraction (HFrEF), and the CYCLE-2-PEF trial is …
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
GlobeNewswire
·
August 6, 2025
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive …
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire
·
August 6, 2025
EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment …
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
GlobeNewswire
·
August 6, 2025
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today …
FOXO TECHNOLOGIES INC. ANNOUNCES EXECUTION OF A NON-BINDING ACQUISITION AGREEMENT FOR AN ASSISTED-LIVING FACILITY IN SOUTH FLORIDA FOR A TOTAL CONSIDERATION OF $22 MILLION
GlobeNewswire
·
August 6, 2025
WEST PALM BEACH, FLORIDA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) announces that it has executed a non-binding acquisition agreement to acquire an assisted living and memory care facility in …
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire
·
August 6, 2025
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …